Answers are grounded in this paper and cite their sources.
Systematic review shows that biologic therapies are cost-effective in inflammatory bowel disease, suggesting improved health outcomes.
Biologic therapies for inflammatory bowel disease are cost-effective, providing significant health benefits that offset higher costs. Substantial methodological heterogeneity and reliance on model-based economic evaluations limit direct comparability across studies. Future economic evaluations should focus on methodological consistency and transparency in assumptions to strengthen the interpretability of cost-effectiveness evidence.
No takes yet. Share an insight, caveat, or question.
Randlová et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: